Most recent papers in the journal European Heart Journal

#1

Coronary artery disease in the absence of traditional risk factors: a call for action.

Suzanne R Avis, Stephen T Vernon, Emil Hagström, Gemma A Figtree

No abstract text is available yet for this article.

34293105

July 22, 2021: European Heart Journal

#2

In the pool: dilution or drowning?

Victor Dayan, Nick Freemantle, Fabio Barili, Patrick Myers, David Taggart

No abstract text is available yet for this article.

34291791

July 22, 2021: European Heart Journal

#3

Effects of canagliflozin on human myocardial redox signalling: clinical implications.

Hidekazu Kondo, Ioannis Akoumianakis, Ileana Badi, Nadia Akawi, Christos P Kotanidis, Murray Polkinghorne, Ilaria Stadiotti, Elena Sommariva, Alexios S Antonopoulos, Maria C Carena, Evangelos K Oikonomou, Elsa Mauricio Reus, Rana Sayeed, George Krasopoulos, Vivek Srivastava, Shakil Farid, Surawee Chuaiphichai, Cheerag Shirodaria, Keith M Channon, Barbara Casadei, Charalambos Antoniades

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects, on myocardial redox signalling in humans. METHODS AND RESULTS: Study 1 included 364 patients undergoing cardiac surgery. Right atrial appendage biopsies were harvested to quantify superoxide (O2...

34293101

July 19, 2021: European Heart Journal

#4

Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study.

Renato Quispe, Seth S Martin, Erin D Michos, Isha Lamba, Roger S Blumenthal, Anum Saeed, Joao A C Lima, Rishi Puri, Sarah O Nomura, Michael Y Tsai, John T Wilkins, Christie M Ballantyne, Stephen J Nicholls, Steven R Jones, Mohamed B Elshazly

AIMS: Emerging evidence suggests that remnant cholesterol (RC) promotes atherosclerotic cardiovascular disease (ASCVD). We aimed to estimate RC-related risk beyond low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) in patients without known ASCVD. METHODS AND RESULTS: We pooled data from 17 532 ASCVD-free individuals from the Atherosclerosis Risk in Communities study (n = 9748), the Multi-Ethnic Study of Atherosclerosis (n = 3049), and the Coronary Artery Risk Development in Young Adults (n = 4735)...

34293083

July 19, 2021: European Heart Journal

#5

Corrigendum to: Pregnancy-associated arterial dissections: a Nationwide cohort study.

(no author information available yet)

No abstract text is available yet for this article.

34279617

July 19, 2021: European Heart Journal

#6

Post-stenting fractional flow reserve vs coronary angiography for optimisation of percutaneous coronary intervention: TARGET-FFR trial.

Damien Collison, Matthaios Didagelos, Muhammad Aetesam-Ur-Rahman, Samuel Copt, Robert McDade, Peter McCartney, Thomas J Ford, John McClure, Mitchell Lindsay, Aadil Shaukat, Paul Rocchiccioli, Richard Brogan, Stuart Watkins, Margaret McEntegart, Richard Good, Keith Robertson, Patrick O'Boyle, Andrew Davie, Adnan Khan, Stuart Hood, Hany Eteiba, Colin Berry, Keith G Oldroyd

AIMS : A fractional flow reserve (FFR) value ≥0.90 after percutaneous coronary intervention (PCI) is associated with a reduced risk of adverse cardiovascular events. TARGET-FFR is an investigator-initiated, single-centre, randomized controlled trial to determine the feasibility and efficacy of a post-PCI FFR-guided optimization strategy vs. standard coronary angiography in achieving final post-PCI FFR values ≥0.90. METHODS AND RESULTS : After angiographically guided PCI, patients were randomized 1:1 to receive a physiology-guided incremental optimization strategy (PIOS) or a blinded coronary physiology assessment (control group)...

34279606

July 19, 2021: European Heart Journal

#7

Endocardial/endothelial angiocrines regulate cardiomyocyte development and maturation and induce features of ventricular non-compaction.

Siyeon Rhee, David T Paik, Johnson Y Yang, Danielle Nagelberg, Ian Williams, Lei Tian, Robert Roth, Mark Chandy, Jiyeon Ban, Nadjet Belbachir, Seokho Kim, Hao Zhang, Ragini Phansalkar, Ka Man Wong, Devin A King, Caroline Valdez, Virginia D Winn, Ashby J Morrison, Joseph C Wu, Kristy Red-Horse

AIMS: Non-compaction cardiomyopathy is a devastating genetic disease caused by insufficient consolidation of ventricular wall muscle that can result in inadequate cardiac performance. Despite being the third most common cardiomyopathy, the mechanisms underlying the disease, including the cell types involved, are poorly understood. We have previously shown that endothelial cell-specific deletion of the chromatin remodeller gene Ino80 results in defective coronary vessel development that leads to ventricular non-compaction in embryonic mouse hearts...

34279605

July 19, 2021: European Heart Journal

#8

Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.

Victor Aboyans, Rupert Bauersachs, Lucia Mazzolai, Marianne Brodmann, José F Rodriguez Palomares, Sebastian Debus, Jean-Philippe Collet, Heinz Drexel, Christine Espinola-Klein, Basil S Lewis, Marco Roffi, Dirk Sibbing, Henrik Sillesen, Eugenio Stabile, Oliver Schlager, Marco De Carlo

The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice...

34279602

July 19, 2021: European Heart Journal

#9

An attempt to reconcile the contrasting results of analyses on implantable cardioverter-defibrillator shocks during the pandemic.

Selçuk Adabag, Mohammad Madjid, Alan Cheng

No abstract text is available yet for this article.

34279030

July 19, 2021: European Heart Journal

#10

Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis.

Julia Hinterdobler, Simin Schott, Hong Jin, Almut Meesmann, Anna-Lena Steinsiek, Anna-Sophia Zimmermann, Jana Wobst, Philipp Müller, Carina Mauersberger, Baiba Vilne, Alexandra Baecklund, Chien-Sin Chen, Aldo Moggio, Quinte Braster, Michael Molitor, Markus Krane, Wolfgang E Kempf, Karl-Heinz Ladwig, Michael Hristov, Maarten Hulsmans, Ingo Hilgendorf, Christian Weber, Philip Wenzel, Christoph Scheiermann, Lars Maegdefessel, Oliver Soehnlein, Peter Libby, Matthias Nahrendorf, Heribert Schunkert, Thorsten Kessler, Hendrik B Sager

AIMS: Mental stress substantially contributes to the initiation and progression of human disease, including cardiovascular conditions. We aim to investigate the underlying mechanisms of these contributions since they remain largely unclear. METHODS AND RESULTS : Here, we show in humans and mice that leucocytes deplete rapidly from the blood after a single episode of acute mental stress. Using cell-tracking experiments in animal models of acute mental stress, we found that stress exposure leads to prompt uptake of inflammatory leucocytes from the blood to distinct tissues including heart, lung, skin, and, if present, atherosclerotic plaques...

34279021

July 19, 2021: European Heart Journal

#11

EDITORIAL

Response to discussion forum letter: an attempt to reconcile the contrasting results of analyses on ICD shocks during the pandemic.

Catherine J O'Shea, Melissa E Middeldorp, Kevin Campbell, Prashanthan Sanders

No abstract text is available yet for this article.

34279020

July 19, 2021: European Heart Journal

#12

Lack of specialist care is associated with increased morbidity and mortality in adult congenital heart disease: a population-based study.

Gerhard-Paul Diller, Stefan Orwat, Astrid Elisabeth Lammers, Robert M Radke, Fernando De-Torres-Alba, Renate Schmidt, Ursula Marschall, Ulrike M Bauer, Dominic Enders, Leo Bronstein, Gerrit Kaleschke, Helmut Baumgartner

AIMS: The aim of this study was to provide population-based data on the healthcare provision for adults with congenital heart disease (ACHD) and the impact of cardiology care on morbidity and mortality in this vulnerable population. METHODS AND RESULTS: Based on administrative data from one of the largest German Health Insurance Companies, all insured ACHD patients (<70 years of age) were included. Patients were stratified into those followed exclusively by primary care physicians (PCPs) and those with additional cardiology follow-up between 2014 and 2016...

34269382

July 16, 2021: European Heart Journal

#13

Erratum to: Personalized anti-thrombotic management of patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1 - a statement of the ESC Working Group on Cardiovascular Pharmacotherapy and ESC Council on Stroke.

(no author information available yet)

No abstract text is available yet for this article.

34269377

July 16, 2021: European Heart Journal

#14

Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial.

N Curzen, Z Nicholas, B Stuart, S Wilding, K Hill, J Shambrook, Z Eminton, D Ball, C Barrett, L Johnson, J Nuttall, K Fox, D Connolly, P O'Kane, A Hobson, A Chauhan, N Uren, G P Mccann, C Berry, J Carter, C Roobottom, M Mamas, R Rajani, I Ford, P Douglas, M A Hlatky

AIMS : Fractional flow reserve (FFRCT) using computed tomography coronary angiography (CTCA) determines both the presence of coronary artery disease and vessel-specific ischaemia. We tested whether an evaluation strategy based on FFRCT would improve economic and clinical outcomes compared with standard care. METHODS AND RESULTS : Overall, 1400 patients with stable chest pain in 11 centres were randomized to initial testing with CTCA with selective FFRCT (experimental group) or standard clinical care pathways (standard group)...

34269376

July 16, 2021: European Heart Journal

#15

Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study.

Myrthe M A Toorop, Qingui Chen, Vladimir Y I G Tichelaar, Suzanne C Cannegieter, Willem M Lijfering

AIMS : Persistence with direct oral anticoagulants (DOACs) has become a concern in non-valvular atrial fibrillation (NVAF) patients, but whether this affects prognosis is rarely studied. We investigated the persistence with oral anticoagulants (OACs) and its association with prognosis among a nationwide cohort of NVAF patients. METHODS AND RESULTS : DOAC-naive NVAF patients who started to use DOACs for ischaemic stroke prevention between 2013 and 2018 were included using Dutch national statistics...

34269375

July 16, 2021: European Heart Journal

#16

ALPK3: a full spectrum cardiomyopathy gene?

Roddy Walsh, Connie R Bezzina

No abstract text is available yet for this article.

34263911

July 15, 2021: European Heart Journal

#17

Alpha-protein kinase 3 (ALPK3)-truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy.

Luis R Lopes, Soledad Garcia-Hernández, Massimiliano Lorenzini, Marta Futema, Olga Chumakova, Dmitry Zateyshchikov, Maria Isidoro-Garcia, Eduardo Villacorta, Luis Escobar-Lopez, Pablo Garcia-Pavia, Raquel Bilbao, David Dobarro, Maria Sandin-Fuentes, Claudio Catalli, Blanca Gener Querol, Ainhoa Mezcua, Jose Garcia Pinilla, Torsten Bloch Rasmussen, Ana Ferreira-Aguar, Pablo Revilla-Martí, Maria Teresa Basurte Elorz, Alicia Bautista Paves, Juan Ramon Gimeno, Ana Virginia Figueroa, Raul Franco-Gutierrez, Maria Eugenia Fuentes-Cañamero, Marina Martinez Moreno, Martin Ortiz-Genga, Jesus Piqueras-Flores, Karina Analia Ramos, Ainars Rudzitis, Luis Ruiz-Guerrero, Ricardo Stein, Mayte Triguero-Bocharán, Luis de la Higuera, Juan Pablo Ochoa, Dad Abu-Bonsrah, Cecilia Y T Kwok, Jacob B Smith, Enzo R Porrello, Mohammed M Akhtar, Joanna Jager, Michael Ashworth, Petros Syrris, David A Elliott, Lorenzo Monserrat, Perry M Elliott

AIMS: The aim of this study was to determine the frequency of heterozygous truncating ALPK3 variants (ALPK3tv) in patients with hypertrophic cardiomyopathy (HCM) and confirm their pathogenicity using burden testing in independent cohorts and family co-segregation studies. METHODS AND RESULTS : In a discovery cohort of 770 index patients with HCM, 12 (1.56%) were heterozygous for ALPK3tv [odds ratio(OR) 16.01, 95% confidence interval (CI) 7.89-29.74, P < 8...

34263907

July 15, 2021: European Heart Journal

#18

Persisting burden and challenges of rheumatic heart disease.

Eloi Marijon, Ana Mocumbi, Kumar Narayanan, Xavier Jouven, David S Celermajer

Rheumatic heart disease (RHD) is the result of episodes of acute rheumatic fever with valvular (and other cardiac) damage caused by an abnormal immune response to group A streptococcal infections, usually during childhood and adolescence. As a result of improved living conditions and the introduction of penicillin, RHD was almost eradicated in the developed world by the 1980s. However, being a disease of poverty, its burden remains disproportionately high in the developing world, despite being a fundamentally preventable disease...

34263296

July 15, 2021: European Heart Journal

#19

Clinician Well-Being-addressing global needs for improvements in the health care field: a joint opinion from the American College of Cardiology, American Heart Association, European Society of Cardiology, World Heart Federation.

Laxmi S Mehta, Mitchell S V Elkind, Stephan Achenbach, Fausto J Pinto, Athena Poppas

No abstract text is available yet for this article.

34254636

July 13, 2021: European Heart Journal

#20

EDITORIAL

Hypercoagulability and thrombosis in COVID-19: a modifiable cause for mortality?

Noel Chan, John Eikelboom